Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) – Research analysts at Oppenheimer issued their Q1 2023 earnings per share (EPS) estimates for Orchard Therapeutics in a research report issued on Monday, March 13th. Oppenheimer analyst H. Singh forecasts that the company will post earnings per share of ($1.50) for the quarter. The consensus estimate for Orchard Therapeutics’ current full-year earnings is ($16.13) per share. Oppenheimer also issued estimates for Orchard Therapeutics’ Q2 2023 earnings at ($1.22) EPS, Q3 2023 earnings at ($1.20) EPS, Q4 2023 earnings at ($1.18) EPS, FY2023 earnings at ($5.06) EPS, FY2024 earnings at ($0.77) EPS, FY2025 earnings at ($0.58) EPS and FY2026 earnings at $0.05 EPS.
Orchard Therapeutics Stock Performance
Shares of ORTX opened at $5.20 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.57 and a quick ratio of 3.57. Orchard Therapeutics has a one year low of $3.60 and a one year high of $8.88. The company has a 50-day simple moving average of $5.59 and a two-hundred day simple moving average of $4.92. The firm has a market capitalization of $65.88 million, a PE ratio of -0.46 and a beta of 0.88.
Hedge Funds Weigh In On Orchard Therapeutics
About Orchard Therapeutics
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies.
- Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.